Diagnostic Screening Programs

诊断性筛查计划
  • 文章类型: Journal Article
    大多数发育筛查测试都是作为父母进行的问卷构建的。然而,他们经常不指导父母如何回答问卷。本研究旨在制定易于适用的家长指南。
    我们与20名小组成员一起实施了Delphi程序。最初问卷的制定是基于政策研究报告提供的父母和专家的两次调查结果,该报告调查了韩国发育筛查测试的项目充分性。第一轮包括33个项目,其中包括六个类别中的所有可能的测量值,这些测量值被确定为难以理解或令人困惑。第二轮合并并修改了一些项目,包括32个项目。我们将共识定义为1或更小的中值一致值以及0.5或更小的收敛和稳定性值。根据他们以前的测试经验,检查了父母指南的主观有用性。
    在第二轮之后达成共识,反映每个类别中准确性最高的项目。在参与调查的167名家长中,113(67.7%)肯定了指南的有用性,10人(6.0%)回答说它们没有用。父母发现在回答问卷时建议采用不同的评分策略的项目对父母更有用。
    父准则,由五个要点组成,取得了专家的共识。需要进一步的研究来评估这些指南是否提高了临床环境中筛查测试的准确性。
    UNASSIGNED: Most developmental screening tests have been built as parent-performed questionnaires. However, they often do not guide parents on how to answer the questionnaire. This study aimed to develop easily applicable parent guidelines.
    UNASSIGNED: We implemented the Delphi procedure with 20 panelists. The development of the initial questionnaire was based on the results of two surveys of parents and experts provided by a policy research report that investigated the item adequacy of the Korean Developmental Screening Test. Round one included 33 items comprising all possible measurements in six categories that were identified as difficult to understand or confusing. Round two merged and modified some items and included 32 items. We defined consensus as a median agreement value of one or less and convergence and stability values of 0.5 or less. The subjective usefulness of the parent guidelines was examined based on their previous test experiences.
    UNASSIGNED: Consensus was reached after the second round, reflecting the items with the highest level of accuracy in each category. Of the 167 parents who participated in the survey, 113 (67.7%) affirmed the usefulness of the guidelines, while 10 (6.0%) answered that they were not useful. Items that recommended a different scoring strategy in answering the questionnaire from their previous measurements were found to be more useful by the parents.
    UNASSIGNED: The parent guidelines, composed of five bullet points, drew on the consensus of the experts. Further studies are required to assess whether these guidelines improve the accuracy of screening tests in clinical settings.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:Idylla表皮生长因子受体(EGFR)是一种快速,全自动的突变测定,易于实施。然而,在Biocartis推荐的技术条件下,将组织切片直接引入药筒中,有耗尽肿瘤样本的风险。在这项研究中,我们评估了IdyllaEGFR在提取DNA上的表现,并讨论了其在全球非小细胞肺癌(NSCLC)筛查策略中的地位.
    方法:在两个中心对IdyllaEGFR提取的DNA和下一代测序(NGS)进行了577项比较试验。
    结果:建立了分析前阈值(肿瘤细胞含量为20%,50ngDNA输入)并在常规实践中前瞻性地挑战。被推荐用于筛选的16.8%的样本被认为不符合IdyllaEGFR检测的条件。由于设计案例的不和谐,对于目前可操作的EGFR突变,IdyllaEGFR敏感性为86.9%。在一线筛选中,IdyllaEGFR特异性为100%。NGS在相同的DNA上总是可行的。
    结论:在提取的DNA上进行IdyllaEGFR是可行的,与使用组织切片相比,可以节省肿瘤材料。没有必要替换Biocartis算法的分析阈值。由于NSCLC中突变库的限制和可靶向基因的高度增加,IdyllaEGFR的使用应仅限于伴有NGS的临床紧急情况.
    OBJECTIVE: Idylla epidermal growth factor receptor (EGFR) is a fast and fully automated mutation assay that is easy to implement. However, under the Biocartis-recommended technical conditions, tissue sections are directly introduced into the cartridge, at the risk of exhausting the tumour sample. In this study, we evaluate the performance of Idylla EGFR on extracted DNA and discuss its place within the global non-small-cell lung cancer (NSCLC) screening strategy.
    METHODS: 577 comparative tests between Idylla EGFR on extracted DNA and next-generation sequencing (NGS) were performed across two centres.
    RESULTS: Preanalytical thresholds were established (20% tumour cell content, 50 ng DNA input) and challenged prospectively in routine practice. 16.8% of samples referred for screening were considered non eligible for Idylla EGFR testing. Due to discordant by design cases, Idylla EGFR sensitivity was 86.9% for currently actionable EGFR mutations. Idylla EGFR specificity was 100% in first-line screening. NGS was always feasible on the same DNA.
    CONCLUSIONS: Idylla EGFR on extracted DNA is feasible and enables tumour material to be saved compared with tissue section use. It is not necessary to replace the analytical thresholds of the Biocartis algorithm. Due to both the limits of the mutational repertoire and the high increase of targetable genes in NSCLC, the use of Idylla EGFR should be restricted to clinical emergency situations accompanied by NGS.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Coronary artery disease (CAD) is a concerning late outcome for cancer survivors. However, uniform surveillance guidelines are lacking.
    To harmonise international recommendations for CAD surveillance for survivors of childhood, adolescent and young adult (CAYA) cancers.
    A systematic literature review was performed and evidence graded using the Grading of Recommendations, Assessment, Development and Evaluation criteria. Eligibility included English language studies, a minimum of 20 off-therapy cancer survivors assessed for CAD, and 75% diagnosed prior to age 35 years. All study designs were included, and a multidisciplinary guideline panel formulated and graded recommendations.
    32 of 522 identified articles met eligibility criteria. The prevalence of CAD ranged from 0 to 72% and was significantly increased compared to control populations. The risk of CAD was increased among survivors who received radiotherapy exposing the heart, especially at doses ≥15 Gy (moderate-quality evidence). The guideline panel agreed that healthcare providers and CAYA cancer survivors treated with radiotherapy exposing the heart should be counselled about the increased risk for premature CAD. While the evidence is insufficient to support primary screening, monitoring and early management of modifiable cardiovascular risk factors are recommended. Initiation and frequency of surveillance should be based on the intensity of treatment exposures, family history, and presence of co-morbidities but at least by age 40 years and at a minimum of every 5 years. All were strong recommendations.
    These systematically assessed and harmonised recommendations for CAD surveillance will inform care and guide research concerning this critical outcome for CAYA cancer survivors.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    After allogeneic stem cell transplant, patients may experience psychiatric, endocrinologic, pulmonary, and cardiovascular problems, as well as secondary malignancies and chronic graft-versus-host disease over the long-term follow-up. These long-term complications not only increase mortality and morbidity of transplant survivors but also decrease their quality of life. In this study, we shared our experiences with our guideline-driven approach for follow-up of long-term complications.
    Our study included 91 patients who received allogeneic hematopoietic cell transplant between July 2009 and March 2016 at our medical center. In accordance with the current guidelines, a screening program was applied to all patients seen between February 2016 and February 2017.
    Median posttransplant follow-up duration was 36 months (range, 12-84 mo), and the median follow-up duration after initial diagnosis was 51 months (range, 15-109 mo). Evaluations of patients posttransplant showed ocular complications (50.6% of patients), oral complications (15.4%), respiratory complications (8.8%), cardiac complications (5.5%), metabolic syndrome (37.4%), liver complications (2.2%), skeletal complications (66.7%), endocrine complications (12.1%), secondary cancers (2.2%), psychosocial adjustment (27.7%), hypertension (5.5%), and type 2 diabetes mellitus (8.8%).
    For long-term follow-up, detailed evaluations of body organs and systems are essential. Early recognition of the aforementioned complications could decrease mortality and morbidity. For patients to be monitored by transplant centers over many years, training and awareness should be provided to ensure adequate follow-up of patients. Based on our results, we believe that the long-term follow-up guidelines used in our clinic are applicable to others.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号